Skip to main content
SpringerLink
Log in

Amantadin

  • Chapter
Book cover Neuro-Psychopharmaka Ein Therapie-Handbuch

Zusammenfassung

Seit der ersten Ausgabe der „Neuro-Psycho-pharmaka“ sind viele neue präklinische Befunde zu Amantadin erhoben worden. Amantadin gehÖrt zur Gruppe der Adamantanamine. Diese Substanzen bestehen aus einer polaren Aminogruppe und dem apolaren Kohlenwasserstoffskelett des Adamantans, welches aus vier gleichartigen, in der Sesselform fixierten Sechsringen besteht (Abb. 7.1.1). Der Name „Adamantan“ leitet sich von „Diamant“ ab und nimmt damit bezug auf die strukturelle Ähnlichkeit der KohlenwasserstoffgerÜste. Die Erstsynthese von Amantadin wurde 1960 beschrieben (Stetter et al. 1960). Wenig später wurde die antivirale Aktivität von Amantadin bekannt (Davies et al. 1964), und 1968 beobachtete eine Patientin unter der Grippeprophylaxe mit Amantadin eine Besserung ihrer Parkinson-Symptomatik (Schwab et al. 1969). Dieser Zufallsbefund konnte bald durch systematische Untersuchungen bestätigt werden (Parkes et al. 1970).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anonymous (1996) Morbus Parkinson. Vigilanz-und AntriebsstÖrungen. Merz + Co, Frankfurt am Main

    Google Scholar 

  • Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366–375

    PubMed  CAS  Google Scholar 

  • Albuquerque EX, Eldefrawi AT, Eldefrawi ME, Mansour NA, Tsai M-C (1978) Amantadine: neuromuscular blockade by supression of ionic conductance of the acetylcholine receptor. Science 199: 788–790

    PubMed  CAS  Google Scholar 

  • Aoki FY, Sitar DS (1988) Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14: 35–51

    PubMed  CAS  Google Scholar 

  • Aoki FY, Sitar DS, Ogilvie RI (1979) Amantadine kinetics in healthy young subjects after long-term dosing. Clin Pharmacol Ther 26: 729–736

    PubMed  CAS  Google Scholar 

  • Aronstam RS, Eldefrawi AT, Eldefrawi ME (1980) Similarities in the binding sites of the muscarinic receptor and the ionic channel of the nicotinic receptor. Biochem Pharmacol 29: 1311–1314

    PubMed  CAS  Google Scholar 

  • Ashcroft FM, Kerr AJ, Gibson JS, Williams BA (1991) Amantadine and sparteine inhibit ATP-regulated K-currents in the insulin-secreting beta-cell line. Br J Pharmacol 104: 579–584

    PubMed  CAS  Google Scholar 

  • Bailey EV, Stone TW (1975) The mechanism of action of amantadine in Parkinsonism: a review. Arch Int Pharmacodyn 216: 246–262

    PubMed  CAS  Google Scholar 

  • Bleidner WE, Harmon JB, Hewes WK, Lynes TE, Hermann EC (1965) Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 150: 484–490

    PubMed  CAS  Google Scholar 

  • Bode L, Dietrich DE, Stoyloff R, Emrich HM, Ludwig H (1997) Amantadine and human borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet 349: 178–179

    PubMed  CAS  Google Scholar 

  • Bowman MA, Kirk JK, Michielutte R, Preisser JS (1997) Use of amantadine for chronic fatigue syndrome. Arch Intern Med 157: 1264–1265

    PubMed  CAS  Google Scholar 

  • Brenner M, Haass A, Jacobi P, Schimrigk K (1989) Amantadine sulphate in treating Parkinson’s disease: clinical effects, psychometric tests and serum concentrations. J Neurol 236: 153–156

    PubMed  CAS  Google Scholar 

  • Brown F, Redfern PH (1976) Studies on the mechanism of action of amantadine. Br J Pharmacol 58: 561–567

    PubMed  CAS  Google Scholar 

  • Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine depleted mice. J Neural Transm 75: 221–226

    PubMed  CAS  Google Scholar 

  • Cha J-HJ, Durel VLS, Sakurai SY, Penney JB, Young AB (1991) 2,4,5-Trihydroxyphenylalanine (6-hydroxy-DOPA) displaces PHIAMPA binding in rat striatum. Neurosci Lett 132: 55–58

    PubMed  CAS  Google Scholar 

  • Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12: 4427–4436

    PubMed  CAS  Google Scholar 

  • Cohen RA, Fisher M (1989) Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 46: 676–680

    PubMed  CAS  Google Scholar 

  • Colman RW, Kuchibhotla J, Jain MK, Murray RK (1977) Phase separation in phosphatidylcholine bilayers as a predictor of inhibition of blood platelet aggregation by amantadines. Biochem Biophys Acta 467: 273–279

    PubMed  CAS  Google Scholar 

  • Cook PE, Dermer SW, Mcgurk T (1986) Fatal overdose with amantadine. Can J Psychiatry 31: 757–758

    PubMed  CAS  Google Scholar 

  • Costall B, Naylor RJ (1975) Neuropharmacological studies on D145. Psychopharmacologia 43: 53–61

    PubMed  CAS  Google Scholar 

  • Danysz W, Essmann U, Bresink I, Wilke R (1994a) Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 48: 111–118

    PubMed  CAS  Google Scholar 

  • Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G (1994b) Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? — Case of amantadine and memantine. J Neural Transm [PD Sect] 7: 155–166

    CAS  Google Scholar 

  • Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies. Neurosci Biobehav Rev 21: 455–468

    PubMed  CAS  Google Scholar 

  • Davies WL, Grunert RR, Haff RF, Mcgahen JW, Neumayer EM, Paulshock M, Watts JC, Wood TR, Hermann EC, Hoffmann CE (1964) Antiviral activity of 1-adamantanamine (amantadine). Science 144: 862–863

    PubMed  CAS  Google Scholar 

  • Dichiara G, Morelli M, Consolo S (1994) Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 17: 228–233

    CAS  Google Scholar 

  • Dimascio A, Bernardo DL, Greenblatt DJ, Marder JE (1976) A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 33: 599–602

    PubMed  CAS  Google Scholar 

  • Dunn JP, Henkel JG, Gianutsos G (1986) Pharmacological activity of amantadine: effect of N-alkyl substitution. J Pharm Pharmacol 38: 353–356

    PubMed  CAS  Google Scholar 

  • Eletr S, Williams MA, Watkins T, Keith AD (1974) Perturbations of the dynamics of lipid alkyl chains in membrane systems: effect on the activity of membrane-bound enzymes. Biochem Biophys Acta 339: 190–201

    CAS  Google Scholar 

  • Farnebo LO, Fuxe K, Goldstein M, Manberg B, Ungerstedt U (1971) Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson’s disease. Eur J Pharmacol 16: 27–38

    PubMed  CAS  Google Scholar 

  • Gianutsos G, Chute S, Dunn JP (1985) Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 110: 357–361

    PubMed  CAS  Google Scholar 

  • Greenamyre JT, O’Brien CF (1991) N-Methyl-D-aspartate antagonists in the treatment of Parkinson’s disease. Arch Neurol 48: 977–981

    PubMed  CAS  Google Scholar 

  • Gualtieri T, Chandler M, Coons TB, Brown LT (1989) Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol 4: 258–270

    Google Scholar 

  • Hayden FG, Hall WJ, Douglas RG, Speers DM (1979) Amantadine aerosols in normal volunteers: pharmacology and safety testing. Antimicrob Agents Chemother 16: 644–650

    PubMed  CAS  Google Scholar 

  • Heikkila RE, Cohen G (1972) Evaluation of amantadine as a releasing agent or uptake blocker for 3H-dopamine in rat brain slices. Eur J Pharmacol 20: 156–160

    PubMed  CAS  Google Scholar 

  • Henkel JG, Hane JT (1982) Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution. J Med Chem 25: 51–56

    PubMed  CAS  Google Scholar 

  • Horadam VW, Sharp JG, Smilack JD, Mcanalley BH, Garriott JC, Stephens MK, Prati RC, Brater DC (1981) Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Int Med 94: 454–458

    PubMed  CAS  Google Scholar 

  • Jackisch R, Link T, Neufang B, Koch R (1992) Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 320: 21–42

    PubMed  CAS  Google Scholar 

  • Janiec W, Piekarska T, Szczypior M, Misterkiewicz E (1977) The effect of apomorphine, amantadine and dimethylaminoadamantane on the level of cyclic AMP in the rat striatum. Pol J Pharmacol Pharm 29: 93–99

    PubMed  CAS  Google Scholar 

  • Janiec W, Piekarska T, Paletko Z, Pytlik M (1978) The effect of drugs stimulating central dopaminergic system on transformation of exogenous adenine into cAMP. Pol J Pharmacol Pharm 30: 529–535

    PubMed  CAS  Google Scholar 

  • Karobath ME (1974) Amantadine and D-145, an amantadine derivative, do not effect dopamine sensitive adenylate cyclase from the caudate-putamen of the rat brain. Eur J Pharmacol 28: 376–378

    PubMed  CAS  Google Scholar 

  • Kelly JT, Zimmerman RL, Abuzzahab FS, Schiele BC (1974) A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced Parkinsonism. Pharmacology 12: 65–73

    PubMed  CAS  Google Scholar 

  • Klockgether T, Turski L (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson’s disease. Trends Neurosci 12: 285–286

    PubMed  CAS  Google Scholar 

  • Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann Neurol 28: 539–546

    PubMed  CAS  Google Scholar 

  • Klockgether T, Turski L (1993) Towards understanding of the role of glutamate in experimental Parkinsonism: agonist sensitive sites in the basal ganglia. Ann Neurol 34: 585–593

    PubMed  CAS  Google Scholar 

  • Knight V, Bloom K, Wilson SZ, Wilson RK (1979) Amantadine aerosol in humans. Antimicrob Agents Chemother 16: 572–578

    PubMed  CAS  Google Scholar 

  • König P, Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H (1996) Amantadine versus biperiden: a double-blind study of treatment-efficacy in neuroleptic EPS. Neuropsychobiology 33: 80–84

    PubMed  Google Scholar 

  • Koppel C, Tenczer J (1985) A revision of the metabolic disposition of amantadine. Biomed Mass Spectrometry 12: 499–501

    CAS  Google Scholar 

  • Kornhuber J, Weller M (1994) Neuroleptic malignant syndrome. Curr Opin Neurol 7: 353–357

    PubMed  CAS  Google Scholar 

  • Kornhuber J, Weller M (1996) Neue therapeutische MÖglichkeiten mit niederaffinen NMDA-Rezeptorantagonisten. Nervenarzt 67: 77–82

    PubMed  CAS  Google Scholar 

  • Kornhuber J, Weller M (1997) Psychotogenicity and NMDA receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41: 135–144

    PubMed  CAS  Google Scholar 

  • Kornhuber J, Bormann J, Retz W, HÜBers M, Riederer P (1989) Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589–590

    PubMed  CAS  Google Scholar 

  • Kornhuber J, Bormann J, HÜBers M, Rusche K, Riederer P (1991) Effects of the 1-amino-ada-mantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol Mol Pharmacol Sect 206: 297–300

    CAS  Google Scholar 

  • Kornhuber J, Schoppmeyer K, Riederer P (1993a) Affinity of 1-aminoadamantanes for the a binding site in post-mortem human frontal cortex. Neurosci Lett 163: 129–131

    PubMed  CAS  Google Scholar 

  • Kornhuber J, Weller M, Riederer P (1993b) Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic Parkinsonian crisis. J Neural Transm [PD Sect] 6: 63–72

    CAS  Google Scholar 

  • Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm [Suppl] 43: 91–104

    CAS  Google Scholar 

  • Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P (1995a) Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34: 713–721

    PubMed  CAS  Google Scholar 

  • Kornhuber J, Retz W, Riederer P (1995b) Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? J Neural Transm [Suppl] 46: 311–319

    Google Scholar 

  • Kraus MF, Maki P (1997a) The combined use of amantadine and 1-dopa/carbidopa in the treatment of chronic brain injury. Brain Inj 11: 455–460

    PubMed  CAS  Google Scholar 

  • Kraus MF, Maki PM (1997b) Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci 9: 222–230

    PubMed  CAS  Google Scholar 

  • Kroemer RT, Koutsilieri E, Hecht P, Liedl KR, Riederer P, Kornhuber J (1998) Quantitative analysis of the structural requirements for blockade of the NMDA receptor at the PCP binding site. J Med Chem 41: 393–400

    PubMed  CAS  Google Scholar 

  • Lampe H, Bigalke H (1991) Modulation of glycine-activated membrane current by adamantane derivatives. NeuroReport 2: 373–376

    PubMed  CAS  Google Scholar 

  • Lassen JB (1973) The effect of amantadine and (+)-amphetamine on motility in rats after inhibition of monoamine synthesis and storage. Psychopharmacologia 29: 55–64

    PubMed  CAS  Google Scholar 

  • Liu P, Cheng PJ, Ing TS, Daugirdas JT, Jeevanandhan R, Soung LS, Galinis S (1984) In vitro binding of amantadine to plasma proteins. Clin Neuropharmacol 7: 149–151

    PubMed  CAS  Google Scholar 

  • Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263: 717–724

    PubMed  CAS  Google Scholar 

  • Lustig HS, Ahern KB, Greenberg DA (1992) Antiparkinsonian drugs and in vitro excitotoxicity. Brain Res 597: 148–150

    PubMed  CAS  Google Scholar 

  • Maj J (1982) Die Wirkung von Memantin auf zentrale Neurotransmittersysteme. Arzneimittelforschung/Drug Res 32: 1256–1259

    CAS  Google Scholar 

  • Maj J, Sowinska H, Baran L (1972) The effect of amantadine on motor activity and catalepsy in rats. Psychopharmacologia 24: 296–307

    PubMed  CAS  Google Scholar 

  • Maj J, Sowinska H, Baran L, Sarnek J (1974) Pharmacological effects of l,3-dimethyl-5-amino-adamantane, a new adamantane derivative. Eur J Pharmacol 26: 9–14

    PubMed  CAS  Google Scholar 

  • Matsubayashi H, Swanson KL, Albuquerque EX (1997) Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. J Pharmacol Exp Ther 281: 834–844

    PubMed  CAS  Google Scholar 

  • Menon MK, Clark WG (1978) Pharmacological evidence for the involvement of GABA-ergic system in the locomotor stimulation produced in mice by l,3-dimethyl-5-aminoada-mantane (D-145). Neuropharmacology 17: 1049–1052

    PubMed  CAS  Google Scholar 

  • Menon MK, Clark WG (1979) GABA-ergic drugs block the locomotor stimulant effects of 1,3-dimethyl-5-aminoadamantane (D-145). Neuropharmacology 18: 223–225

    PubMed  CAS  Google Scholar 

  • Menon MK, Vivonia CA, Haddox VG (1984) Evidence for presynaptic antagonism by amantadine of indirectly acting central stimulants. Psychopharmacology Berl 82: 89–92

    PubMed  CAS  Google Scholar 

  • Mizuno Y, Mori H, Kondo T (1994) Potential of neuroprotective therapy in Parkinsons disease. CNS Drugs 1: 45–56

    Google Scholar 

  • Moryl E, Danysz W, Quack G (1993) Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 72: 394–397

    PubMed  CAS  Google Scholar 

  • Müller T, Kuhn W, Quack G, Przuntek H (1995) Intravenous application of amantadine and antiparkinsonian efficacy in Parkinsonian patients. J Neural Transm 46: 407–413

    Google Scholar 

  • Northoff G, Eckert J, Fritze J (1997) Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMD A antagonist amantadine. J Neurol Neurosurg Psychiatry 62: 404–406

    PubMed  CAS  Google Scholar 

  • Olney JW, Price MT, Labruyere J, Salles KS, Friedrich G, Mueller M, Silverman E (1987) Anti-parkinsonian agents are phencyclidine agonists and N-methyl-D-aspartate antagonists. Eur J Pharmacol 142: 319–320

    PubMed  CAS  Google Scholar 

  • Ossowska K (1994) The role of excitatory amino acids in experimental models of Parkinson’s disease. J Neural Transm [PD-Sect] 8: 39–71

    CAS  Google Scholar 

  • Papeschi R (1974) Amantadine may stimulate dopamine and noradrenaline receptors. Neuropharmacology 13: 77–83

    PubMed  CAS  Google Scholar 

  • Parkes D (1974) Amantadine. In: Harper NJ, Simmonds AB (eds) Advances in drug research. Academic Press, London, pp 11–81

    Google Scholar 

  • Parkes JD, Zilkha KJ, Calver DM, Knill-Jones RP (1970) Controlled trial of amantadine hydrochloride in Parkinson’s disease. Lancet i: 259–262

    Google Scholar 

  • Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34: 1239–1258

    PubMed  CAS  Google Scholar 

  • Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA (1996) Comparative patch clamp studies with freshly dissociated rat hippocampal and striatal neurones on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 8:446–454

    PubMed  CAS  Google Scholar 

  • Perrin DD, Hawkins I (1972) Dissociation constant of the 1-aminoadamantane cation. Experientia 28: 880

    CAS  Google Scholar 

  • Raffa RB, Ortegón ME, Robisch DM, Martin GE (1989) In vivo demonstration of the enhancement of MK-801 by L-glutamate. Life Sci 44: 1593–1599

    PubMed  CAS  Google Scholar 

  • Rausch WD, Schallauer E, Chan WW, Riederer P, Weiser M (1990) Effects of L-deprenyl and amantadine in an MPTP-model of Parkinsonism. J Neural Transm [Suppl 32]: 269–275

    Google Scholar 

  • Reiser G, Koch R (1989) Memantine inhibits serotonin-induced rise of cytosolic Ca2+ activity and of cytosolic GMP level in a neuronal cell line. Eur J Pharmacol Mol Pharmacol Sect 172: 199–203

    CAS  Google Scholar 

  • Reiser G, Binmöller F-J, Koch R (1988) Memantine (1-amino-3,5-dimethyladamantane) blocks the serotonin-induced depolarization response in a neuronal cell line. Brain Res 443: 338–344

    PubMed  CAS  Google Scholar 

  • Rizzo M, Biandrate P, Tognoni G, Morselli PL (1973) Amantadine in depression: relationship between behavioural effects and plasma levels. Eur J Clin Pharmacol 5: 226–228

    CAS  Google Scholar 

  • Rojas P, Altagracia M, Kravsov J, Rios C (1992) Partially protective effect of amantadine in the MPTP model of Parkinson’s disease. Proc West Pharmacol Soc 35: 33–35

    PubMed  CAS  Google Scholar 

  • Rosenberg GA, Appenzeller O (1988) Amantadine, fatigue, and multiple sclerosis. Arch Neurol 45: 1104–1106

    PubMed  CAS  Google Scholar 

  • Schmidt WJ, Bubser M (1989) Anti-cataleptic effects of the N-methyl-aspartate antagonist MK-801. Pharmacol Biochem Behav 32: 621–623

    PubMed  CAS  Google Scholar 

  • Schmidt WJ, Bubser M, Hauber W (1990) Excitatory amino acids and Parkinson’s disease. Trends Neurosci 13: 46–47

    PubMed  CAS  Google Scholar 

  • Schmidt WJ, Bubser M, Hauber W (1992) Behavioural pharmacology of glutamate in the basal ganglia. J Neural Transm [Suppl] 38: 65–89

    CAS  Google Scholar 

  • Schwab RS, England AC, Poskanzer DC, Young RR (1969) Amantadine in the treatment of Parkinson’s disease. JAMA 208: 1168–1170

    PubMed  CAS  Google Scholar 

  • Silver H, Geraisy N, Schwartz M (1995) No difference in the effect of biperiden and amantadine on Parkinsonian — and tardive dyskinesia — type involuntary movements: a double blind crossover, placebo-controlled study in medicated chronic schizophrenic patients [published erratum J Clin Psychiatry 56 (1995) 435]. J Clin Psychiatry 56: 167–170

    Google Scholar 

  • Simpson DM, Ramos F, Ramirez LF (1988) Death of a psychiatric patient from amantadine poisoning. Am J Psychiatry 145: 267–268

    PubMed  CAS  Google Scholar 

  • Skuza G, Rogoz Z, Quack G, Danysz W (1994) Memantine, amantadine, and L-deprenyl potentiate the action of L-DOPA in monoaminedepleted rats. J Neural Transm [Gen Sect] 98: 57–67

    CAS  Google Scholar 

  • Sonsalla PK, Nicklas WJ, Heikkila RE (1989) Role of excitatory amino acids in methampheta-mine-induced nigrostriatal dopaminergic toxicity. Science 343: 398–400

    Google Scholar 

  • Soung L-S, Ing TS, Daugirdas JT, Wu M-J, Gandhi VC, Ivanovich PT, Hano JE, Viol GW (1980) Amantadine hydrochloride pharmacokinetics in hemodialysis patients. Ann Intern Med 93: 46–49

    PubMed  CAS  Google Scholar 

  • Spector R (1988) Transport of amantadine and rimantadine through the blood-brain barrier. J Pharmacol Exp Ther 244: 516–519

    PubMed  CAS  Google Scholar 

  • Starr MS (1995) Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson’s disease. Synapse 19: 264–293

    PubMed  CAS  Google Scholar 

  • Stetter H, Mayer J, Schwarz M, Wulff K (1960) Beiträge zur Chemie der Adamantyl-(1)-Derivate. Chem Ber 93: 226–230

    CAS  Google Scholar 

  • Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213: 439–443

    PubMed  CAS  Google Scholar 

  • Svensson TH (1973) Dopamine release and direct dopamine receptor activation in the central nervous system by D-145, an amantadine derivative. Eur J Pharmacol 23: 232–238

    PubMed  CAS  Google Scholar 

  • Tilley JW, Kramer MJ (1981) Aminoadamantane derivates. Progr Med Chem 18: 1–44

    CAS  Google Scholar 

  • Turski L, Bressler K, Rettig K-J, Löschmann P-A, Wachtel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349: 414–418

    PubMed  CAS  Google Scholar 

  • Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology 46: 1551–1556

    PubMed  CAS  Google Scholar 

  • Vale S, Espejel MA, Dominguez JC (1971) Amantadine in depression. Lancet ii: 437

    Google Scholar 

  • Weller M, Kornhuber J (1992) Pathophysiologie und Therapie des malignen neuroleptischen Syndroms. Nervenarzt 63: 645–655

    PubMed  CAS  Google Scholar 

  • Weller M, Finiels-Marlier F, Paul SM (1993) NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 613: 143–148

    PubMed  CAS  Google Scholar 

  • Wenk GL, Danysz W, Mobley SL (1995) MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magno-cellularis. Eur J Pharmacol 293: 267–270

    PubMed  CAS  Google Scholar 

  • Wesemann W (1983) Adamantanamine — neurobiologische Untersuchungen zur klinischen Wirkung einer polizyklischen Verbindungsklasse mit diamantähnlicher Struktur. Funkt Biol Med 2: 137–145

    CAS  Google Scholar 

  • Wesemann W, Ekenna O (1982) Effect of 1-amino-adamantanes on the MAO activity in brain, liver, and kidney of the rat. Arzneimittelfor-schung/Drug Res 32: 1241–1243

    CAS  Google Scholar 

  • Wesemann W, Schollmeyer JD, Sturm G (1977) Gaschromatographische und massenspektro-metrische Untersuchungen über harnpflichtige Metabolite von Adamantanaminen. Arzneimittelf orschung/Drug Res 27: 1471–1477

    CAS  Google Scholar 

  • Wesemann W, Dette-Wildenhahn G, Fellehner H (1979) In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson. J Neural Transm 44: 263–285

    PubMed  CAS  Google Scholar 

  • Wesemann W, Sturm G, Fünfgeld EW (1980) Distribution and metabolism of the potential anti-parkinson drug memantine in the human. J Neural Transm [Suppl] 16: 143–146

    Google Scholar 

  • Wesemann W, Sontag K-H, Maj J (1983) Zur Pharmakodynamik und Pharmakokinetik des Memantin. Arzneimittelforschung/Drug Res 33: 1122–1134

    CAS  Google Scholar 

Literatur

  • Alterman AJ, Droba M, Antelo RE, Cornish JW, Sweeney KR, Parikh CA, O’Brian CP (1992) Amantadine may facilitate detoxification of cocaine addicts. Drug-Alcohol Depend 31: 19–29

    PubMed  CAS  Google Scholar 

  • Ambrozi L, Danielczyk W (1988) Die Behandlung zerebraler FunktionsstÖrungen mit Memantine bei psychogeriatrischen Patienten — Ergebnisse einer Phase-II-Doppelblindstudie. Pharmacopsychiatry 21: 144–146

    PubMed  CAS  Google Scholar 

  • Amdurski S, Radwan M, Levi A, Elizur A (1983) A therapeutic trial of amantadine in haloperidol-induced malignant neuroleptic syndrome. Curr Ther Res 33: 225–229

    Google Scholar 

  • Aoki FY, Sitar DS (1985) Amantadine kinetics in healthy elderly men: implications for influenza prevention. Clin Pharmacol Ther 37: 137–144

    PubMed  CAS  Google Scholar 

  • Appleton DB, Eadie MJ, Sutherland JM (1970) Amantadine hydrochloride in the treatment of Parkinsonism: a controlled trial. Med J Aust 2: 626–629

    PubMed  CAS  Google Scholar 

  • Baehr M, Eschweiler GW, Dichgans J (1994) Neuronal protection in neurological disease? Nervenarzt 65: 355–360

    Google Scholar 

  • Blanchard DL (1990) Amantadine caused corneal edema (letter). Cornea 9: 181

    PubMed  CAS  Google Scholar 

  • Borman J (1989) Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 166: 591–592

    Google Scholar 

  • Botez MJ, Young SN, Botez T, Pedraza OL (1991) Treatment of heredodegenerative ataxias with amantadine hydrochloride. Can J Neurol Sci 18: 307–311

    PubMed  CAS  Google Scholar 

  • Brenner M, Haas A, Jacobi P, Schimrigk K (1989) Amantadine sulphate in treating Partinson’s disease: clinical effects, psychometric tests and serum concentrations. J Neurol 23: 153–156

    Google Scholar 

  • Chandler MC, Barnhill JJ, Gualtierei CT (1988) Amantadine for the agitated head injury patient. Brain Injury 2: 309–311

    PubMed  CAS  Google Scholar 

  • Chen HS, Pellegrini JW, Aggarval SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open channel block of N-methyl-D-aspartate (NMDA) responses by memantine; therapeutic advantage against NMDA-receptor-mediated neurotoxity. J Neurosci 12: 4427–4436

    PubMed  CAS  Google Scholar 

  • Chiba S, Ito M, Matsumoto H (1992) Amantadme treatment for refractory pain and fatigue in patients with multiple sclerosis. Can J Neurol Sci 19: 309

    PubMed  CAS  Google Scholar 

  • Cohen RA, Fisher M (1989) Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 46: 676–680

    PubMed  CAS  Google Scholar 

  • Cook PE, Dermer SW, Mcgurk T (1986) Fatal overdose with amantadine. Can J Psychiatry 31: 757–758

    PubMed  CAS  Google Scholar 

  • Danielczyk W (1973) Die Behandlung von akinetischen Krisen. Vortrag. Amantadin-Symposium, Bad Nauheim

    Google Scholar 

  • Danielczyk W (1979a) MeditkamentÖs ausgelÖste Psychosen bei neurologisch erkrankten älteren Menschen. Akt Gerontol 9: 427–431

    CAS  Google Scholar 

  • Danielczyk W (1979b) Akute pharmakotoxische Psychosen bei chronischen zerebralen Erkrankungen. Wien Med Wochenschr 129[Suppl 55]: 1–15

    Google Scholar 

  • Danielczyk W (1995) Twenty-five years of amantadine therapy in Parkinson’s disease. J Neural Transm [Suppl] 46: 395–401

    Google Scholar 

  • Davies JR, Grilli EA, Smith AJ, Hoskins TW (1988) Prophylactic use of amantadine in a boarding school outbreak of influenza A. J Roy Coll Gen Pract 38: 346–348

    CAS  Google Scholar 

  • Delay J, Deniker P (1968) Drug induced extrapyramidal syndromes. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology, vol 6. Diseases of the basal ganglia. North Holland, Amsterdam, pp 248–266

    Google Scholar 

  • Drake ME Jr, Pakalnis A, Demo LS, Phillips B (1991) Amantadine hydrochloride for refractory generalized epilepsy in adults. Acta Neurol Belg 91: 159–164

    PubMed  Google Scholar 

  • Dunn MG (1991) Post-polio fatigue treated with amantadine. Arch Neurol 48: 570

    PubMed  CAS  Google Scholar 

  • Erkulwaters S, Pillai R (1989) Amantadine and the end-stage dementia of Alzheimer’s type. South Med J 82: 550–554

    Google Scholar 

  • Fahn S, Craddock G, Kumin G (1971) Acute toxic psychosis from suicidal overdosage of amantadine. Arch Neurol 25: 45–48

    PubMed  CAS  Google Scholar 

  • Filla A, De-Michele G, Orefice G, Santorelli F, Trombetta L, Banfi S, Squitieri F, Napolitano G, Puma D, Campanella G (1993) A double cross-over trial of amantadine hydrochloride in Friedreich’s ataxia. Can J Neurol Sci 20: 52–55

    PubMed  CAS  Google Scholar 

  • Fisher DA (1982) Recurrent herpes simplex sciatica and its treatment with amantadine hydrochloride. Cutis 29: 467–472

    PubMed  CAS  Google Scholar 

  • Fraunfelder FT, Meyer SM (1990) Amantadine and corneal deposits. Am J Ophthalmol 110: 96–97

    PubMed  CAS  Google Scholar 

  • Fünfgeld EW (1970) Amantadinwirkung bei Parkinsonismus. Dtsch Med Wochenschr 95: 1834–1836

    PubMed  Google Scholar 

  • Fünfgeld EW (1972) Zweijährige Erfahrungen mit der Amantadintherapie bei Parkinsonismus. Ther Woche 39: 3282–3299

    Google Scholar 

  • Fünfgeld EW (1985) Erfahrungen mit Memantin bei der Behandlung extrapyramidaler und pyramidaler BewegungsstÖrungen. Med Praxis 80: 3–7

    Google Scholar 

  • Galbraith AW (1983) Prevention of post-herpetic neuralgy by amantadine hydrochloride (Symmetrel). Br J Clin Pract 37: 304–306

    PubMed  CAS  Google Scholar 

  • Greenamyre JT, O’Brian CF (1991) N-Methyl-D-Aspartate antagonists in the treatment of Parkinson’s disease. Arch Neurol 48: 977–981 (and comment in Arch Neurol [1992] 49: 900–901)

    PubMed  CAS  Google Scholar 

  • Grossmann W, Schütz W (1982) Memantine und neurogene BlasenstÖrungen im Rahmen spastischer Zustandsbilder. Arzneimittelfor-schung/Drug Res 32: 1273–1276

    CAS  Google Scholar 

  • Hamburg P, Weilburg JB, Cassem NH, Cohen L, Brown S (1986) Relapse of neuroleptic malignant syndrome with early discontinuation of amantadine therapy. Compr Psychiatry 27: 272–275

    PubMed  CAS  Google Scholar 

  • Horiguchi J, Inami Y, Shoda T (1990) Effects of long-term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clin Neuropharmacol 13: 84–86

    PubMed  CAS  Google Scholar 

  • Jackson GG, Muldoon RL, Akers LW (1968) Serological evidence for prevention of influenza infection in volunteers by an antiinfluenzal drug: adamantanamin hydrochloride. Anti-microb Agents Chemother 3: 703–707

    Google Scholar 

  • Jörg J (1987) Therapie des Parkinsonsyndroms. Prakt Arzt 570: 1619–1622

    Google Scholar 

  • Kelly JT, Abuzzahab FS (1971) The antiparkinson properties of amantadine in drug-induced parkinsonism. J Clin Pharm 11: 211–214

    CAS  Google Scholar 

  • Kemp BA, Gora ML (1993) Amantadine and fatigue of multiple sclerosis. Ann Pharmacother 27: 893–895

    PubMed  CAS  Google Scholar 

  • Kornhuber J, Weller M, Riederer P (1993) Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm [PD-Sect] 6: 63–72

    CAS  Google Scholar 

  • Kornhuber J, Weller M (1993) Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm [Gen-Sect] 92: 57–65

    CAS  Google Scholar 

  • Kosten TR, Morgan CM, Falcione J, Schottenfeld RS (1992) Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 49: 894–898

    PubMed  CAS  Google Scholar 

  • Kugler J (1975) Influence of aminoamantadine sulphate on vigilance and awareness. Acta Neurol 2: 43–51

    Google Scholar 

  • Kunzelmann V (1993) Oral combination therapy of zoster neuralgia. Pain reduction by 1-aman-tadine sulfate and carbamazepine per os. Fort-schr Med 111: 423–425

    CAS  Google Scholar 

  • Lammers GJ, Roos BA (1993) Hyponatremia due to amantadine hydrochloride and L-dopa/car-bidopa (letter). Lancet 348: 439

    Google Scholar 

  • Leskow P (1987) Therapie zentral bedingter BewegungsstÖrungen. Multicenterstudie mit Memantine. Therapiewoche 37: 4843–4845

    Google Scholar 

  • Leskow P, Lachenmeyer L (1992) Parkinson therapy, yesterday, today, tomorrow. Neuroprotection gains in importance. Fortschr Med 110: 589–592

    PubMed  CAS  Google Scholar 

  • Lieb W, May G (1972) On the treatment of herpetic keratitis with a new amantadine derivative. Klin Monatsbl Augenheilkd 161: 197–206

    PubMed  CAS  Google Scholar 

  • Mcevoy JP (1987) A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. J Clin Psychiatry 48 [Suppl]: 20–23

    PubMed  Google Scholar 

  • Mcevoy JP, Mccue M, Freter S (1987) Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia. Clin Ther 9: 429–433

    PubMed  CAS  Google Scholar 

  • Merrick EM, Schmitt PP (1973) A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel). Curr Ther Res 15: 552–558

    PubMed  CAS  Google Scholar 

  • Miller KS, Miller JM (1994) Toxic effects of amantadine in patients with renal failure (letter). Chest 105: 1630

    PubMed  CAS  Google Scholar 

  • Miltner FO (1982) Wertigkeit der symptomatischen Therapie mit Memantine beim cerebralen Koma. I. Korrelation von Komastadien und EEG-Spektralverläufen. Arzneimittelfor-schung/Drug Res 32: 1268–1270

    CAS  Google Scholar 

  • Mitchell G (1993) Update on multiple sclerosis therapy. Med Clin North Am 77: 231–249

    PubMed  CAS  Google Scholar 

  • Morgan MY (1991) The treatment of chronic hepatic encephalopathy. Hepatogastroenterology 38: 377–387

    PubMed  CAS  Google Scholar 

  • Moryl E, Danysz W, Quack G (1993) Potential antidepressive properties of amantadine, memantine and bifemelane. J Pharmacol Toxicol 72: 394–397

    CAS  Google Scholar 

  • Mostow SR (1987) Prevention, management and control of influenza. Role of amantadine. Am J Med 82: 35–41

    CAS  Google Scholar 

  • Muller SR, Dastoor DP, Klinger A, Boillat J (1979) Amantadine in senile dementia: electroencephalographic and clinical effects. J Am Geriatr Soc 27: 9–16

    PubMed  CAS  Google Scholar 

  • Murray TJ (1985) Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 12: 251–254

    PubMed  CAS  Google Scholar 

  • Nestelbaum Z, Siris SG, Rifkin A, Klar H, Reardon GT (1986) Exacerbation of schizophrenia associated with amantadine. Am J Psychiatry 143: 1170–1171

    PubMed  CAS  Google Scholar 

  • Nickels JL, Schneider WN, Dombovy ML, Wong TM (1994) Clinical use of amantadine in brain injury rehabilitation. Brain Inj 8: 709–718

    PubMed  CAS  Google Scholar 

  • Nogaki H, Morimatsu M (1993) Superficial punctate keratitis and corneal abrasion due to amantadine hydrochloride (letter). J Neurol 240: 388–389

    PubMed  CAS  Google Scholar 

  • Ott L (1983) Klinische Beobachtungen und Erfahrungen mit Memantine bei spastischen BewegungsstÖrungen. Klinikarzt 12 [Suppl]: 19–20

    Google Scholar 

  • Pacifici GM, Nardini M, Ferrari P, Latini R, Fieschi C, Marselli PL (1976) Effect of amantadine on drug-induced Parkinsonism: relationship between plasma levels and effect. Br J Clin Pharmacol 3: 883–889

    PubMed  CAS  Google Scholar 

  • Pandit PB, Chytayat D, Jefferies AL, Landes A, Qamar IV, Koren G (1994) Tibial hemimelia and tetralogy of Fallot associated with first trimester exposure to amantadine. Reprod Toxicol 8: 89–92

    PubMed  CAS  Google Scholar 

  • Parkes JD, Zilka KJ, Calver DM, Knill-Jones RP (1970) Controlled trial of amantadine hydrochloride in Parkinson’s disease. Lancet i: 259–262

    Google Scholar 

  • Parkes JD (1971) Side-effects in Parkinson’s disease. A new approach to treatment. In: Birdwood GFB, Gilder SS, Wink CAS (eds). Academic Press, London New York, p 72

    Google Scholar 

  • Pellegrini JW, Lipton SA (1993) Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 33: 403–407

    PubMed  CAS  Google Scholar 

  • Peterson PL, Saad J, Nigro MA (1988) The treatment of Friedreich’s ataxia with amantadine hydrochloride. Neurology 38:1478–1480

    PubMed  CAS  Google Scholar 

  • Rabey JM, Nissipeanu P, Korczyn AD (1992) Efficacy of memantine, an NMD A receptor antagonist, in the treatment of Parkinson’s disease. J Neural Transm 4: 277–282

    CAS  Google Scholar 

  • Riederer P, Lange KW, Kornhuber J, Danielczyk W (1992) Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelfor-schung/Drug Res 42: 256–268

    Google Scholar 

  • Robertson DR, George CF (1990) Treatment of post-herpetic neuralgia in the elderly. Br Med Bull 46: 113–123

    PubMed  CAS  Google Scholar 

  • Roca RP, Santmyer R, Gloth FM, Denman SJ (1990) Improvements in activity and appetite among long-term care patients treated with amantadine. A clinical report. J Am Geriatr Soc 38: 675–677

    PubMed  CAS  Google Scholar 

  • Rohde H (1982) Ergebnisse klinischer PrÜfungen des Antispastikums Memantine. Fortschr Med 43: 2023–2026

    Google Scholar 

  • Rojtman M, Apter E, Lahav S, Tiano S (1981) Amantadine in malignant neuroleptic syndrome (Hebrew with English Abstract). Harefuah 100: 333–334

    PubMed  CAS  Google Scholar 

  • Rosa F (1994) Amantadine pregnancy experience (letter). Reprod Toxicol 8: 531

    PubMed  CAS  Google Scholar 

  • Rosenberg GA, Appenzeller D (1988) Amantadine, fatigue and multiple sclerosis. Arch Neurol 45: 1104–1106

    PubMed  CAS  Google Scholar 

  • Rumpf KW, Rummel J, Meinhold J, Clemens C (1990) Schwere Nebenwirkungen von Amantadin bei Niereninsuffizienz. Dtsch Ärztebl 87: 352

    Google Scholar 

  • Sandyk R, Jacono RP, Snider SR (1987) Amantadine for levodopa resistent parkinsonism. Int Neurosci 32: 715–717

    CAS  Google Scholar 

  • Schinitsy MR (1992) Reversal of neurologic deficits in Down syndrome. Am J Dis Child 146: 783

    PubMed  CAS  Google Scholar 

  • Schubert H, König P, Schultes H, Havelec L (1995) Amatadine versus biperidin: a double-blind study of treatment efficacy in neuroleptic EPS. J Neural Transm [Gen Sect] 102: XLI (Abstract)

    Google Scholar 

  • Schwab RS, England Jr AC, Poskaner DC (1969) Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc 208: 1163–1170

    Google Scholar 

  • Sears SD, Clements ML (1987) Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob Agents Chemother 31: 1470–1473

    PubMed  CAS  Google Scholar 

  • Segal AW (1985) Variations on the theme of chronic granulomatous disease. Lancet i: 1378–1383

    Google Scholar 

  • Shahar EM, Brand H (1992) Effect of add-on amantadine therapy for refractory absence epilepsy. J Pediatr 121: 819–821

    PubMed  CAS  Google Scholar 

  • Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL (1987) Amantadine and motor fluctuations in chronic Parkinson’s disease. Clin Neuropharmacol 10: 522–526

    PubMed  CAS  Google Scholar 

  • Silver H, Geratsy N, Schwartz M (1995) No difference in the effect of biperiden and amantadine on parkinsonian and tardive dyskinesia-type involuntary movements: a double-blind, cross-over, placebo-controlled study in medicated chronic schizophrenia patients. J Clin Psychiatry 56: 167–170

    PubMed  CAS  Google Scholar 

  • Snoey ER, Bessen HA (1990) Acute psychosis after amantadine overdose. Ann Emerg Med 19: 668–670

    PubMed  CAS  Google Scholar 

  • Starr MS (1995) Antiparkinsonian action of glutamate antagonists — alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms. J Neural Transm [PD Sect] 10: 141–185

    CAS  Google Scholar 

  • Stewart JT (1987) Adverse behavioral effects of amantadine therapy in Huntington’s disease. South Med J 80: 1324–1325

    PubMed  CAS  Google Scholar 

  • Stoof JC, Booij J, Drukarch B (1992) Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol Neurosurg 94 [Suppl]: S4–S6

    PubMed  Google Scholar 

  • Streifler M, Kallay V (1972) Amantadine in Parkinson’s disease. Harefuah 82: 499–502 (Hebrew with English Abstract)

    PubMed  CAS  Google Scholar 

  • Streifler M, Hait Z (1973) Amantadinderivate bei Parkinsonismus im Blindversuch. Therapiewoche 40: 3549–3652

    Google Scholar 

  • Streifler M, Avrami E (1975) Levodopa and the secretion of sebum in parkinsonian patients. Eur Neurol 19: 43–48

    Google Scholar 

  • Taylor WA, Gold MS (1990) Pharmocologic approaches to the treatment of cocaine dependence. West J Med 152: 573–577

    PubMed  CAS  Google Scholar 

  • Tennant FS, Sagherian AA (1987) Double blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocainie dependence. Arch Int Med 147: 109–112

    Google Scholar 

  • Thompson DF (1992) Amantadine in the treatment of cocaine withdrawal. Ann Pharmacother 26: 933–934

    PubMed  CAS  Google Scholar 

  • Toru M, Matsuda D, Makiguchi K, Sugano K (1981) Neuroleptic malignant syndrome — like state following withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 169: 324–327

    PubMed  CAS  Google Scholar 

  • Turski L (1991) Excitatory amino acid antagonists and Parkinson’s disease. In: Rinne UK, Nagatsaku T, Horowski R (eds) International Workshop Berlin — Parkinson’s disease. Bussum (Netherlands) Medicom, pp 97–112

    Google Scholar 

  • Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P (1995) Improved survival in Parkinson’s disease with use of amantadine. J Neural Transm [Gen Sect] 102: XLIX (Abstract)

    Google Scholar 

  • van Reekum R, Bayley M, Garner S, Burke JM, Fawcett S, Hart A, Thompson W (1995) Amantadine for the a-motivational syndrome in a patient with traumatic brain injury. Brain Inj 9: 49–53

    PubMed  Google Scholar 

  • Vardi J, Streifler M (1975) On the synchronizing effect of amantadine-1-hydrochloride (Symmetrel) on pathological EEG activity. J Neural Transm 37: 73–80

    PubMed  CAS  Google Scholar 

  • Warner JD (1985) Amantadine in chronic granulomatous disease (letter). Lancet ii: 1024–1027

    Google Scholar 

  • Weddington WW Jr, Brown BS, Haertzen CA, Hess JM, Mahaffey JB, Kolar AF, Jaffe JH (1991) Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug-Alcohol-Abuse 17: 137–152

    PubMed  Google Scholar 

  • Weller M, Kornhuber J (1992) A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Med Hypotheses 38: 329–333

    PubMed  CAS  Google Scholar 

  • Weller M, Kornhuber J (1993) Amantadine withdrawal and neuroleptic malignant syndrome. Neurology 43: 2155

    PubMed  CAS  Google Scholar 

  • Wilcox JA, Tsuang J (1990) Psychological effects of amantadine on psychotic subjects. Neuropsychobiology 23: 144–146

    PubMed  Google Scholar 

  • Winkler A (1973) Die Behandlung herpetischer Dermatosen mit einem neuartigen Virustaticum. Med Welt 24: 1024–1027

    PubMed  CAS  Google Scholar 

  • Woo J, Teoh R, Vallance-Owen J (1986) Neuroleptic malignant syndrome successfully treated with amantadine. Postgrad Med J 62: 809–810

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. Kornhuber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Wiltfang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Streifler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Bezirkskrankenhaus Gabersee, Wasserburg/Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, Österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Wien

About this chapter

Cite this chapter

Kornhuber, J., Wiltfang, J., Streifler, M. (1999). Amantadin. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6400-6_31

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7315-2

  • Online ISBN: 978-3-7091-6400-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation